Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Sanofi Exits Diabetes R&D, Meaning Of ‘Diabetes R&D’ Blurs

Executive Summary

Cardiovascular outcome trials are driving development in blockbuster SGLT-2 inhibitor and GLP-1 agonist classes to look beyond HbA1c levels to focus on cardiovascular and renal protective effects.

You may also be interested in...



How The Failure Of US PBM Reform Shaped Sanofi’s Decision To Exit Diabetes R&D

And how in contrast, Novo Nordisk is launching its oral GLP-1 agonist for diabetes at a price that may set up 'business as usual' tensions with pharmacy benefit managers and payers.

Sanofi, Long-Time Leader In Diabetes, Is Exiting Diabetes Research

The company's decision to exit diabetes research is not necessarily surprising given the development and commercial challenges in the therapeutic area, but it's not insignificant either.

Empagliflozin Likely Needs Another Trial After Rebuke By US FDA Panel

Expanded indication for type 1 diabetes seems out of reach for the moment, but if Boehringer conducts a larger and lengthier trial, it could eventually persuade members of the Endocrinologic and Metabolic Drugs Advisory Committee who voted 14-2 against supplemental approval of empagliflozin for the proposed 2.5mg dose.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141392

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel